Investigation Launched Against Viatris Inc. over Alleged Securities Law Violations
New York, NY – In a recent development, Levi & Korsinsky, a leading securities law firm, announced that it has initiated an investigation into Viatris Inc. (Viatris) (NASDAQ:VTRS) over potential securities law violations. The investigation comes in the wake of Viatris’ fourth quarter and full year 2024 financial results, which fell short of consensus estimates for key metrics as disclosed in a press release on February 27, 2025.
Background
Viatris is a global healthcare company that was formed in late 2020 through the merger of Mylan N.V. and Pfizer Inc.’s Upjohn business. The company focuses on developing, manufacturing, and marketing a range of generic, branded, and biosimilar medicines. Viatris’ product portfolio spans various therapeutic areas, including cardiovascular disease, pain management, and respiratory conditions, among others.
Financial Results Miss Consensus Estimates
In its press release, Viatris reported that its net sales for the fourth quarter of 2024 were $4.6 billion, which was below the consensus estimate of $4.7 billion. The company also reported a GAAP net loss of $1.1 billion for the quarter due to one-time charges and other items. This loss was wider than the consensus estimate of a net loss of $929 million. For the full year 2024, Viatris reported net sales of $16.7 billion, which was also below the consensus estimate of $16.8 billion.
Investigation Details
Levi & Korsinsky is investigating whether Viatris and certain of its officers or directors violated securities laws by making false and/or misleading statements and/or failing to disclose material information to investors. Specifically, the investigation focuses on whether Viatris made false and/or misleading statements and/or failed to disclose: (1) that the company’s financial results for the fourth quarter and full year 2024 would miss consensus estimates, and (2) that, as a result of this, Viatris’ public statements were materially false and misleading at all relevant times.
Impact on Individual Investors
If you are a Viatris investor or held a position in Viatris securities between February 25, 2021, and February 28, 2025, you may be entitled to compensation. Levi & Korsinsky encourages investors to contact the firm as soon as possible to discuss their potential remedies. You can call 212-363-7535 or submit the form on the firm’s website: [email protected]
Global Implications
The impact of this investigation on the global healthcare industry could be significant, as it highlights the importance of transparency and accuracy in financial reporting. Viatris’ misreported financial results could lead to a loss of investor trust and potentially impact other companies in the sector. Additionally, the investigation could result in increased regulatory scrutiny and potential penalties for Viatris. It is essential for all companies to ensure that they are providing accurate and timely financial information to investors to maintain trust and confidence in the markets.
Conclusion
In conclusion, the investigation launched by Levi & Korsinsky into Viatris Inc. over potential securities law violations following the release of financial results that missed consensus estimates is a concerning development for the healthcare sector. The implications for individual investors and the global markets could be substantial, and it is crucial for companies to prioritize transparency and accuracy in their financial reporting to maintain investor trust and confidence. If you are a Viatris investor and believe you may be entitled to compensation, contact Levi & Korsinsky as soon as possible to discuss your potential remedies.
- Levi & Korsinsky launches investigation into Viatris Inc.
- Investigation focuses on potential securities law violations.
- Viatris reported financial results missed consensus estimates.
- Individual investors potentially entitled to compensation.
- Global implications for healthcare industry and markets.
